Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study

Answers are grounded in this paper and cite their sources.

• What was the primary endpoint, and how big was the effect?
• What are the main limitations?
• How does this compare with earlier trials?